S. Atrchian

Clinical outcomes of pancoast tumors treated with trimodality therapy

M. Humer, J. Siever, A. Lin, 2020, Journal of thoracic disease.

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2022, JAMA oncology.

Primary care provider-led cancer survivorship care in the first 5 years following initial cancer treatment: a scoping review of the barriers and solutions to implementation.

M. Stork, M. Vis-Dunbar, S. Atrchian, 2022, Journal of cancer survivorship : research and practice.

Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial.

N. Chng, S. Tyldesley, R. Olson, 2022, International journal of radiation oncology, biology, physics.

The microbiome and breast cancer: a review

M. Manjili, M. Habibi, V. Prasath, 2019, Breast Cancer Research and Treatment.

Improvement of consistency in delineating breast lumpectomy cavity using surgical clips.

L. Helyer, J. Robar, D. Rheaume, 2018, The Journal of surgical research.

Patient Outcomes With Dose Escalation Using Modern Radiotherapy Techniques: A Retrospective Review of Anal Cancer Treated at a Large Academic Institution Between 2010 and 2016

K. DeVries, S. Atrchian, S. Murchison, 2020, Cureus.

Training and Validation of Deep Learning-Based Auto-Segmentation Models for Lung Stereotactic Ablative Radiotherapy Using Retrospective Radiotherapy Planning Contours

T. Teke, C. Kolbeck, V. Huang, 2021, Frontiers in Oncology.

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Predictors of early polymetastatic relapse following stereotactic ablative radiotherapy for up to 5 oligometastases: a secondary analysis of the phase II SABR-5 trial.

N. Chng, S. Tyldesley, Mengxing Liu, 2022, International journal of radiation oncology, biology, physics.

Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial.

N. Chng, S. Tyldesley, Mengxing Liu, 2022, International journal of radiation oncology, biology, physics.